On November 30th, 2021
A Phase II Open Label Trial of Neo-Adjuvant Abemaciclib with Fulvestrant in Patients Who Develop Localized Recurrence While on Adjuvant Endocrine Therapy with Molecular Evidence of Endocrine Resistance
Who We ARE:
Advocacy - Your Voice in State & National Advocacy
Relationships - Your Partner in Cancer Care
Education: Administration, Business, Clinical
JOIN OR RENEW NOW
Advocacy - Your Voice in State & National Advocacy
Relationships - Your Partner in Cancer Care
Education: Administration, Business, Clinical
Contact
- P.O. Box 161
- Upland, CA 91785
- P: 909-985-9061
- F: 909-804-5006
- moasc@moasc.org
No comments have been posted yet.